Skip to main content
. 2023 Feb 3;15:69–86. doi: 10.2147/CEOR.S377399

Table 6.

One-Way Sensitivity Analysis Results

Quality-Adjusted Life Expectancy (QALYs) Cost (SEK) ICUR (SEK Per QALY Gained)
Placebo SQ Tree SLIT-Tablet Δ Placebo SQ Tree SLIT-Tablet Δ
Base case 7.951 7.992 +0.041 103,981 113,057 +9077 223,445
0% discount rate 9.041 9.087 +0.046 118,233 123,880 +5647 122,266
5% discount rate 7.342 7.380 +0.038 96,012 106,927 +10,914 290,985
5 year time horizon 4.308 4.330 +0.022 56,338 80,918 +24,580 1,116,840
15 year time horizon 11.003 11.060 +0.056 143,892 139,981 −3911 Dominant
No mortality 8.083 8.125 +0.041 105,705 114,402 +8696 210,592
Same HCP interactions in placebo arm as the SQ Tree SLIT-Tablet arm 7.951 7.992 +0.041 124,546 113,057 −11,489 Dominant
Same HCP interaction frequency in placebo and SQ Tree SLIT-Tablet arms, GP only 7.951 7.992 +0.041 109,911 113,057 +3147 77,461
Productivity loss based on birch pollen season 7.951 7.992 +0.041 64,526 84,955 +20,429 502,920
No indirect costs 7.951 7.992 +0.041 2550 43,921 +41,371 1,018,468
No productivity loss for HCP interactions 7.951 7.992 +0.041 103,981 112,062 +8082 198,960
No symptom-relieving medication costs 7.951 7.992 +0.041 101,430 111,055 +9624 236,930
No disease-modifying effect with SQ Tree SLIT-Tablet (10 years of SLIT) 7.951 7.992 +0.041 103,981 193,785 +89,804 2,210,793
No disease-modifying effect with SQ Tree SLIT-Tablet (no effects on productivity loss, absenteeism, symptom-relieving medication use, or QoL after treatment) 7.951 7.965 +0.014 103,981 135,537 +31,557 2,314,583
Persistence in line with Allam et al 7.951 7.964 +0.012 103,981 106,703 +2723 223,445

Abbreviations: GP, general practitioner; HCP, healthcare professional; ICUR, incremental cost-utility ratio; SEK, 2021 Swedish Krona; QALY, quality-adjusted life year; QoL, quality of life.